CNO

Cappuccino

Score: 0.432 Price: $0.43 Low Druggability Status: active Wiki: CNO

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

DEBATES

3D Protein Structure

🧬 CNO — PDB 7MFW Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.30

Clinical Stage

Phase III

Target Class

Other

Safety

0.30

Druggability Analysis

Drug Development0.45

Structural Tractability0.70

Target Class0.50

Safety Profile0.30

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (1 compounds)

Therapeutic Areas:

Neurodegeneration (Parkinson's disease-related pathways) Lysosomal storage disorders Pigmentation disorders Chemogenetic research tools

Druggability Rationale: Clozapine-N-oxide (CNO) demonstrates limited druggability for neurodegeneration due to its lack of established direct therapeutic mechanisms and minimal clinical validation in neurodegenerative contexts. While CNO has been primarily utilized as a research tool, particularly in chemogenetic studies, its potential as a direct neurodegeneration therapeutic remains speculative, with current clinical trials focusing on psychosis-related indications rather than neurodegenerative disease modification. The structural complexity and absence of clear target-specific binding profiles suggest CNO requires significant medicinal chemistry optimization to emerge as a promising neurodegeneration drug candidate.

Mechanism: No established druggable mechanisms

Drug Pipeline (1 compounds)

Known Drugs:

Clozapine-N-oxide (research) — DREADD ligand, chemogenetic tool compound

Structural Data:

PDB (1) ✓AlphaFold ✓Cryo-EM —

7MFW

UniProt: Q9NUP1

Binding Pocket Analysis:

Structural data (PDB: 7MFW, AlphaFold available) is limited to single PDB entry with uncharacterized resolution, suggesting potential intrinsically disordered regions typical of trafficking proteins. No characterized ATP-binding site or classical ligand-binding pocket has been identified; binding modulation may require targeting allosteric surfaces or protein-protein interaction interfaces rather than traditional orthosteric sites.

🔮 Predicted Protein Structure (AlphaFold)

🔮 CNO — AlphaFold Q9NUP1 Click to expand interactive 3D viewer

AI-predicted structure from AlphaFold EBI | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

As a unique intracellular trafficking protein with limited homologs, CNO offers potential for high selectivity and low off-target risk. However, selectivity challenges may arise if targeting protein-protein interaction interfaces critical to melanosome trafficking complexes, requiring careful validation of effects on related trafficking machinery.